Global Markets for Bioengineered Protein Drugs

Apr 2023| BIO009H| BCC Publishing
Sample Report

Report Highlights

The global market for bioengineered protein drugs is estimated to increase from $354.1 billion in 2022 to reach $521.3 billion by 2027, at a compound annual growth rate (CAGR) of 8.0% from 2022 through 2027.

Report Includes

  • 28 data tables and 23 additional tables
  • An up-to-date overview and analysis of the global markets for bioengineered protein drugs
  • Analyses of the global market trends, with historic market revenue data (sales figures) from 2019-2021, estimates for 2022, forecasts for 2023, and projections of compound annual growth rates (CAGRs) through 2027
  • Highlights of the emerging technology trends, opportunities and gaps estimating current and future demand for bioengineered protein drugs market, and major regions and countries involved in market developments
  • Estimation of the actual market size and revenue forecast for global bioengineered protein drugs market in USD million terms, and corresponding market share analysis by drug type, disease type, and region
  • In-depth information (facts and figures) concerning the major factors influencing the progress of this market (benefits, and industry-specific challenges) with respect to specific growth trends, upcoming technologies, future prospects, and contributions to the overall biopharmaceutical industry
  • Discussion of the regulatory aspects and standards for bioengineered protein therapeutics, newly approved products, underlying clinical trials for all phases and list of vaccines, and the COVID-19 impact on the progress of this market
  • Insight into the recent industry structure, competitive aspects of each product segment, increasing investment on R&D activities to develop new and improved therapies, market development strategies, and company value share analysis
  • Identification of the major companies involved in the production and modification of protein drugs, and analysis of the company competitive landscape based on their recent developments, financial performance, and segmental revenues
  • Descriptive company profiles of the leading global players, including AbbVie Inc., AstraZeneca plc, GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMS) Co., Pfizer Inc., Merck and Co., and Sanofi S.A.

Report Scope

This report aims to provide a comprehensive study of the global market for bioengineered protein drugs, both in terms of quantitative and qualitative data, to help readers develop business/growth strategies, assess the market landscape, analyze their position in the current marketplace and make informed business decisions regarding bioengineered protein drugs. Segmentation is based on the drug type, disease type, and region.

Industry growth drivers, restraints, trends, and opportunities in bioengineered protein drugs are also discussed in detail. The report also provides information on the bioengineered protein drug market competitive landscape, features detailed company profiles, and discusses the impact of COVID-19 on the market.

Frequently Asked Questions (FAQs)

The global bioengineered protein drugs market is projected to grow from $354.1 billion in 2022 to $521.3 billion in 2027, at a compound annual growth rate (CAGR) of 8.0% during the forecast period.
The global bioengineered protein drugs market is estimated to grow at a healthy rate from 2022 to 2027 based upon a number of factors including:
  • A growing and aging population,
  • Increasing prevalence of chronic diseases,
  • Advancements in manufacturing technologies,
  • New product launches and label expansions,
  • Premium pricing for innovative drugs and
  • Growing demand in emerging markets
The Bioengineered protein drugs market is segmented based on drug type, disease type, and region.
By Type, monoclonal antibodies will dominate the market by the end of 2027.
Notable players in the bioengineered protein drug market are AbbVie Inc., Amgen Inc., Bayer AG (Bayer Healthcare Corp.), Biogen Idec, CSL Behring Ltd., Eli Lilly & Co., GlaxoSmithKline, Merck KGaA, Johnson & Johnson (Janssen Pharmaceutical Inc.), Merck & Co., Novo Nordisk, Pfizer Inc., F. Hoffmann-La Roche Ltd., and Sanofi S.A.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Report Synopsis

Report Metrics Details
Base year considered 2021
Forecast period considered 2022-2027
Base year market size $327.6 billion
Market size forecast $521.3 billion
Growth rate CAGR of 8.0% for the forecast period of 2022-2027
Units considered $ Millions
Segments covered By Drug Type, Disease Type, and Region
Regions covered North America, Europe, and Emerging markets
Key Market Drivers
  • Growing and Aging Population
  • Increasing Prevalence of Chronic Diseases
  • Advancements in Manufacturing Technologies
  • New Product Launches and Label Expansions
  • Premium Pricing
  • Collaborations and Licensing Agreements
Companies studied
  • BIONTECH SE
  • CSL LTD.
  • GLAXOSMITHKLINE PLC
  • GRIFOLS S.A.
  • ABBVIE INC.
  • ADMA BIOLOGICS INC.
  • AMGEN INC.
  • ASTRAZENECA PLC
  • BAYER PHARMACEUTICALS
  • BRISTOL-MYERS SQUIBB
  • ELI LILLY AND CO.
  • F. HOFFMANN-LA ROCHE AG
  • JOHNSON & JOHNSON
  • MERCK & CO., INC.
  • NOVARTIS AG
  • NOVO NORDISK A/S
  • OCTAPHARMA AG
  • PFIZER INC.
  • REGENERON PHARMACEUTICALS INC.
  • SANOFI
  • TAKEDA PHARMACEUTICAL CO., LTD.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
. Title/Chapter NamePagesPrice Member Price
Full Report: Global Markets for Bioengineered Protein Drugs185 $5,500 Free
Chapter- 1: Introduction5Free DownloadFree
Chapter- 2: Summary and Highlights2$250Free
Chapter- 3: Market and Technology Background7$208Free
Chapter- 4: Market Dynamics5$149Free
Chapter- 5: Market Breakdown by Drug Type30$892Free
Chapter- 6: Market Breakdown by Disease29$862Free
Chapter- 7: Market Breakdown by Region11$327Free
Chapter- 8: Regulatory Aspects and New Approvals11$327Free
Chapter- 9: Competitive Landscape12$357Free
Chapter- 10: Emerging Trends/Upcoming Technologies in the Market3$89Free
Chapter- 11: Impact of COVID-19 Pandemic4$119Free
Chapter- 12: Company Profiles66$1,962Free
Published - Jan-2017| Analyst - Shalini Shahani Dewan| Code - BIO009G

Report Highlights

The global market for bioengineered protein drugs is expected to reach $228.4 billion by 2021 from $172.5 billion in 2016, rising at a compound annual growth rate (CAGR) of 5.8% from 2016 through 2021.

Report Includes

  • An overview of the global market for bioengineered protein drugs.
  • Analyses of global market trends, with data from 2014 and 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021.
  • Coverage of proteins that are used for therapeutic purposes, including an analysis of protein-based drugs in clinical trials.
  • A look at current technologies underlying the market as well as the effects new technologies will have on the market.
  • An analysis of the patent landscape in this field and the companies with the greatest breadth in their IP portfolios.
  • Profiles major companies involved in the production and modification of protein drugs.
Published - Aug-2014| Analyst - Shalini Shahani Dewan| Code - BIO009F

Report Highlights

The global market for bioengineered protein drugs was valued at $151.9 billion in 2013 and will reach about $157.0 billion in 2014. The market is further expected to grow to about $222.7 billion in 2019, a compound annual growth rate (CAGR) of 7.2% from 2014 through 2019.

Report Includes

  • An overview of the global market for bioengineered protein drugs.
  • Analyses of global market trends, with data from 2013, estimates for 2014, and projections of compound annual growth rates (CAGRs) through 2019.
  • Coverage of proteins that are used for therapeutic purposes, including an analysis of protein-based drugs in clinical trials.
  • A look at current technologies underlying the market as well as the effects new technologies will have on the market.
  • An analysis of the patent landscape in this field and the companies with the greatest breadth in their IP portfolios.
  • Profiles of the major companies involved in the production and modification of protein drugs.
Published - Jan-2007| Analyst - Gargi Talukder| Code - BIO009E

Report Highlights

  • The total global market for protein drugs was $47.4 billion in 2006. The market will reach $55.7 billion by the end of 2011, an average annual growth rate (AAGR) of 3.3%.
  • Modified and engineered antibodies present the largest share of the total global market. In 2006, this sector held almost 56% of the global market. By the end of 2011 its share will drop slightly but not significantly to 54%.
  • Hormone protein drugs have the largest AAGR through the forecast period, averaging 5.1% through 2011 to reach $11.9 billion by 2011.

Published - Jan-2004| Analyst - Robert Cyran| Code - BIO009D

Report Highlights

  • In 2002, drug companies sold nearly $33 billion in protein drugs, and they are projected to approach $40 billion in 2003.
  • Rising at an average annual growth rate (AAGR) of 12.2%, this market is expected to reach $71 billion in 2008.
  • Replacement proteins constitute the bulk of the market and will rise at an AAGR of 9.8% from $31.4 billion in 2003 to $50 billion in 2008.
  • Monoclonal antibodies and fusion proteins will rise from $8.5 billion in 2003 to $20.1 billion in 2008.
  • These products effectively strip market share from older, less effective therapies. Most notably, a number of monoclonal antibodies are in the last stages of clinical trials for the treatment of autoimmune disease and cancer and promise to be blockbuster products.

Global Markets for Bioengineered Protein Drugs

Single User License: $5500

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.

RELATED REPORTS